Myeloma bone disease: from biology findings to treatment approaches

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Ročník 133; číslo 14; s. 1534
Hlavní autoři: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Dimopoulos, Meletios A
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 04.04.2019
Témata:
Bone Diseases - drug therapy
Bone Diseases - etiology
Denosumab - therapeutic use
Humans
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Osteocytes - pathology
ISSN:1528-0020, 1528-0020
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregulate bone turnover and result in bone loss and skeletal-related events. Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations in this constantly evolving field are thoroughly discussed.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1528-0020
1528-0020
DOI:10.1182/blood-2018-11-852459